Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

926
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
926
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

314
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
314
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

347
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
347
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

758
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
758
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.5K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.5K
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

673
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
673

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Explainable Artificial Intelligence (xAI) for 5-HT<sub>2A</sub> Receptor Binding Affinity of New Psychoactive Substances.

Molecules (Basel, Switzerland)·2026
Same author

Target Attainment and Population Pharmacokinetics of Cefazolin in Patients with Invasive <i>Staphylococcus aureus</i> Infections: A Prospective Cohort Study.

Antibiotics (Basel, Switzerland)·2024
Same author

Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection.

The Journal of antimicrobial chemotherapy·2024
Same author

Machine Learning-Based Analysis Reveals Triterpene Saponins and Their Aglycones in <i>Cimicifuga racemosa</i> as Critical Mediators of AMPK Activation.

Pharmaceutics·2024
Same author

Pharmacokinetics and Pharmacodynamics of Inhaled Nicotine Salt and Free-Base Using an E-cigarette: A Randomized Crossover Study.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2024
Same author

BOHEMIA: Broad One Health Endectocide-based Malaria Intervention in Africa-a phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in two African settings.

Trials·2023

Related Experiment Video

Updated: Apr 4, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.9K

Improving Population Pharmacokinetic Modelling with Artificial Patients using Generative Artificial Intelligence.

Verena Schöning1, Felix Hammann1

  • 1Clinical Pharmacology and Toxicology, Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.

Pharmacology Research & Perspectives
|April 3, 2026
PubMed
Summary
This summary is machine-generated.

Generative artificial intelligence (AI) can create artificial patient profiles to enhance population pharmacokinetic (PopPK) datasets. Augmenting data with AI improved parameter estimates and confidence intervals in pharmacokinetic modeling.

Keywords:
Wasserstein generative adversary networksdata set augmentationordinary differential equationspopulation pharmacokinetics

More Related Videos

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

9.6K
Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

1.3K

Related Experiment Videos

Last Updated: Apr 4, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.9K
Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

9.6K
Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

1.3K

Area of Science:

  • Pharmacokinetics
  • Pharmacodynamics
  • Artificial Intelligence
  • Machine Learning

Background:

  • Non-linear mixed effects (NLME) models are crucial in population pharmacokinetics (PopPK) for analyzing drug concentration-effect relationships.
  • Machine learning (ML) is increasingly utilized in PopPK for tasks like data preparation and predictive modeling, but integrating generated data remains challenging.
  • Current applications of artificially generated information in PopPK are limited, necessitating exploration of novel data augmentation techniques.

Purpose of the Study:

  • To evaluate the efficacy of generative artificial intelligence (AI) in creating artificial patient profiles for augmenting PopPK datasets.
  • To assess the impact of AI-generated data on the accuracy and robustness of pharmacokinetic parameter estimates.
  • To demonstrate a proof-of-concept for using generative AI to improve PopPK modeling.

Main Methods:

  • Defined pharmacokinetic parameters for a hypothetical drug and simulated concentration-time data for 20 patients.
  • Employed Wasserstein Generative Adversarial Networks with Gradient Penalty (WGAN-GP) to generate artificial patient data.
  • Utilized Maximum Mean Discrepancy (MMD) test to confirm statistical indistinguishability between real and generated data distributions.
  • Combined varying proportions of original and artificial data to build and compare PopPK models.

Main Results:

  • WGAN-GP generated artificial patient data that was statistically indistinguishable from the original data, indicating no overfitting or underfitting.
  • The inclusion of artificial patients resulted in narrower confidence intervals for parameter estimates, suggesting enhanced robustness.
  • Generative AI augmentation highlighted the allometric relationship between patient weight and the volume of distribution.

Conclusions:

  • Generative AI offers a viable method for augmenting pharmacokinetic datasets, serving as a proof-of-concept for data augmentation.
  • The preliminary findings suggest that AI-driven data augmentation can lead to more precise and reliable pharmacokinetic parameter estimation.
  • This approach holds promise for improving the efficiency and accuracy of PopPK studies.